M&A Deal Summary

Kriya Therapeutics Acquires Warden Bio

On January 7, 2022, Kriya Therapeutics acquired life science company Warden Bio

Acquisition Highlights
  • This is Kriya Therapeutics’ 1st transaction in the Life Science sector.
  • This is Kriya Therapeutics’ 1st transaction in the United States.

M&A Deal Summary
Date 2022-01-07
Target Warden Bio
Sector Life Science
Buyer(s) Kriya Therapeutics
Deal Type Add-on Acquisition

Target

Warden Bio

United States
Warden Bio is a company developing novel AAV-mediated gene therapies for glycogen storage disorders (GSDs). Warden Bio is based in United States.

Search 192,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Kriya Therapeutics

Redwood City, California, United States

website

Category Company
Sector Life Science
DESCRIPTION

Kriya Therapeutics is a fully integrated company provides novel technologies and therapeutics in gene therapy. Kriya is organized into four principal business units: Kriya Technologies™, Kriya Therapeutics™, Kriya R&D™, and Kriya Manufacturing™. Kriya Therapeutics is based in Redwood City, California.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Add-on Acquisition) 1 of 2
Country (United States) 1 of 1
Year (2022) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-09-06 Tramontane

Barcelona, Spain

Tramontane is a gene therapy company focused on developing treatments for prevalent neurodegenerative and metabolic diseases. Tramontane uses adeno-associated viral vectors to express therapeutic proteins of relevance in the management of multiple diseases, including Non-alcoholic steatohepatitis (NASH), Type 2 diabetes, Obesity, Alzheimer’s disease, Parkinson disease, and other central disorders associated with impaired cognition and behavior.

Buy -
Mergr

Product

Company

Legal